Ibex Ltd

IBEX remains in an early Stage 1 consolidation within a long-term uptrend. Price has repaired its 9/21 EMA regime and is range-bound, suggesting cautious accumulation. Medium-term directional bias is modestly bullish, but short-term timing is neutral, warranting deferred execution into pullbacks around EMA support.

• ↑Q3 revenue of $164.4M rose 17% YoY, driven by 53.7% health tech growth.
• ↑Adjusted EPS grew 11% YoY to $0.91, boosting adjusted EBITDA margins.
• ↓Largest client accounts for 10% of revenue, indicating concentration risk.